跳至內容

依諾妥珠單抗

維基百科,自由的百科全書
依諾妥珠單抗
單株抗體
種類?
目標B7-H3
臨床資料
其他名稱MGA271
ATC碼
  • 未分配
識別資訊
CAS號1353485-38-7
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6474H9990N1726O2030S42
摩爾質量145,829.71 g·mol−1

依諾妥珠單抗INN:Enoblituzumab;開發代號:MGA271)是一種單株抗體,設計用於治療癌症。[1]該藥物是一種人源化IgG1κ單株抗體,可識別人類B7-H3(免疫調節劑B7家族的成員)。[2]

該藥物由MacroGenics公司開發。[3]

參考資料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
  2. ^ Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B.; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for Immunotherapy of Cancer. 2022-04, 10 (4) [2024-03-12]. ISSN 2051-1426. PMC 9006844可免費查閱. PMID 35414591. doi:10.1136/jitc-2021-004424. (原始內容存檔於2024-06-16). 
  3. ^ Enoblituzumab (anti-B7-H3) – MacroGenics. macrogenics.com. [2024-03-12]. (原始內容存檔於2024-03-12).